CCR investigators among world leaders in sarcoma research

Rhabdomyoscarcoma cells

Rhabdomyoscarcoma cells

To recognize Sarcoma Awareness Month this July, we are highlighting some of our researchers who are advancing research discovery in this field. We have a concentration of investigators studying pediatric sarcomas. Dr. Jack Shern's lab uses next generation genomic and molecular assays to understand rhabdomyosarcoma. Dr. Javed Khan is pursuing the application of genomic techniques in the investigation of pediatric cancers like rhabdomyosarcoma to identify biomarkers and novel therapeutic targets and to translate these findings to the clinic. Dr. Brigitte Widemann is developing new therapies for the treatment of pediatric cancers including sarcomas. Dr. Frederic Barr’s research focuses on recurrent chromosomal alteration in sarcomas, with an emphasis on rhabdomyosarcoma, as a biomarker for diagnosis and treatment. Dr. Paul Meltzer is investigating the genetic and epigenetic basis of bone and soft tissue sarcomas in children and adults. Dr. Jing Huang is studying the role of p53, a cancer suppressor, in osteosarcoma and mesenchymal stromal/stem cells, which are thought to be cells that can develop into osteosarcoma. Drs. Robert Yarchoan, Giovanna Tosato, and Joseph Ziegelbauer are focusing on Kaposi sarcoma by studying its pathways and mechanisms of action with the aim of identifying therapeutic targets and developing new treatments for this HIV-associated cancer. Our Comparative Oncology Program, headed by Dr. Amy LeBlanc, is studying sarcomas in pet dogs, who develop cancer naturally like humans, to gain a better understanding of these tumors and to investigate novel treatments for people.

Explore our website further to learn about other CCR researchers who are conducting sarcoma research.

CCR has several clinical trials on sarcoma currently open and enrolling. Learn more.


Summary Posted: 07/2016